Japanese encephalitis vaccine - Kaketsuken

Drug Profile

Japanese encephalitis vaccine - Kaketsuken

Alternative Names: Encevac; Jeimmugen Inj1; KD-287; Vero Cell-derived Inactivated Japanese Encephalitis Vaccine KD-287

Latest Information Update: 07 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kaketsuken
  • Developer Astellas Pharma; Boryung Pharmaceutical; Kaketsuken
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Japanese encephalitis

Most Recent Events

  • 01 Feb 2013 Boryung Pharmaceutical completes a phase III trial in Japanese encephalitis (infants; prevention) in South Korea (NCT01150942)
  • 16 Jul 2010 Phase-III clinical trials planned in prevention of Japanese encephalitis (in paediatric patients aged 12-23 months) in South Korea (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top